Back to News
Mar 25, 2026 12:01 PM

Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

The United Laboratories International Holdings Limited and Novo Nordisk A/S (NYSE:NVO) reported Wednesday topline data from a phase 2 trial in China showing that UBT251, a triple receptor agonist.

Semaglutide is a key ingredient in the famed Wegovy and Ozempic.

UBT251 is designed to challenge Eli Lilly & Co.'s (NYSE:LLY) ‘Triple G' obesity drug, retatrutide, which has already shown promising weight loss results.

UBT251 Shows Superior Glycemic Control And Weight Loss

The once-weekly injectable UBT251 targets GLP-1, GIP, and glucagon receptors, positioning it within a growing class of multi-agonist therapies. The candidate is being co-developed by United Bio-Technology and Novo Nordisk under a March 2025 agreement.

Under ...